151 related articles for article (PubMed ID: 37031717)
21. Terlipressin in hepatorenal syndrome: Evidence for present indications.
Rajekar H; Chawla Y
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
[TBL] [Abstract][Full Text] [Related]
22. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.
Allegretti AS; Israelsen M; Krag A; Jovani M; Goldin AH; Schulman AR; Winter RW; Gluud LL
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD005162. PubMed ID: 29943803
[TBL] [Abstract][Full Text] [Related]
23. Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients.
Dagher L; Patch D; Marley R; Moore K; Burroughs A
Aliment Pharmacol Ther; 2000 May; 14(5):515-21. PubMed ID: 10792112
[TBL] [Abstract][Full Text] [Related]
24. Terlipressin in the management of liver disease.
Scheinberg AR; Martin P; Turkeltaub JA
Expert Opin Pharmacother; 2023; 24(15):1665-1671. PubMed ID: 37535437
[TBL] [Abstract][Full Text] [Related]
25. Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
Israelsen M; Krag A; Allegretti AS; Jovani M; Goldin AH; Winter RW; Gluud LL
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011532. PubMed ID: 28953318
[TBL] [Abstract][Full Text] [Related]
26. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
Int J Artif Organs; 2009 Mar; 32(3):133-40. PubMed ID: 19440988
[TBL] [Abstract][Full Text] [Related]
27. Noradrenaline as an alternative medical treatment to terlipressin in the management of hepatorenal syndrome type 1.
Sendra C; Silva Ruiz MDP; Ferrer Rios MT; Alarcón García JC; Pascasio Acevedo JM
Gastroenterol Hepatol; 2018; 41(7):440-441. PubMed ID: 29054321
[No Abstract] [Full Text] [Related]
28. Noradrenaline or terlipressin for hepatorenal syndrome?
Celis P; Rada G
Medwave; 2015 Aug; 15 Suppl 2():e6235. PubMed ID: 26334297
[TBL] [Abstract][Full Text] [Related]
29. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.
Nassar Junior AP; Farias AQ; D' Albuquerque LA; Carrilho FJ; Malbouisson LM
PLoS One; 2014; 9(9):e107466. PubMed ID: 25203311
[TBL] [Abstract][Full Text] [Related]
30. What is the role for terlipressin in hepatorenal syndrome?
Bass SN; Kapoor A; Lindenmeyer CC
Cleve Clin J Med; 2023 Nov; 90(11):664-667. PubMed ID: 37914199
[No Abstract] [Full Text] [Related]
31. Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1.
Kalambokis GN; Baltayiannis G; Christodoulou D; Christou L
Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1428-1429. PubMed ID: 29111999
[No Abstract] [Full Text] [Related]
32. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K;
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of treatment with terlipressin plus albumin in hepatorenal syndrome diagnosed with the new acute kidney injury versus the conventional criteria.
Kalambokis GN; Christaki M; Tsiakas I; Despotis G; Milionis HJ
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1292-1294. PubMed ID: 31498285
[No Abstract] [Full Text] [Related]
34. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
Sagi SV; Mittal S; Kasturi KS; Sood GK
J Gastroenterol Hepatol; 2010 May; 25(5):880-5. PubMed ID: 20074149
[TBL] [Abstract][Full Text] [Related]
35. Letter: real-world use of terlipressin in patients with hepatorenal syndrome.
Weng F
Aliment Pharmacol Ther; 2021 Aug; 54(3):349. PubMed ID: 34236098
[No Abstract] [Full Text] [Related]
36. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.
Uriz J; Ginès P; Cárdenas A; Sort P; Jiménez W; Salmerón JM; Bataller R; Mas A; Navasa M; Arroyo V; Rodés J
J Hepatol; 2000 Jul; 33(1):43-8. PubMed ID: 10905585
[TBL] [Abstract][Full Text] [Related]
37. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
Ganne-Carrié N; Hadengue A; Mathurin P; Durand F; Erlinger S; Benhamou JP
Dig Dis Sci; 1996 Jun; 41(6):1054-6. PubMed ID: 8654133
[TBL] [Abstract][Full Text] [Related]
38. Editorial: treating hepatorenal syndrome-a window and the views.
Palaniyappan N; Aithal GP
Aliment Pharmacol Ther; 2020 Sep; 52(5):895-896. PubMed ID: 32852817
[No Abstract] [Full Text] [Related]
39. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.
Alessandria C; Ottobrelli A; Debernardi-Venon W; Todros L; Cerenzia MT; Martini S; Balzola F; Morgando A; Rizzetto M; Marzano A
J Hepatol; 2007 Oct; 47(4):499-505. PubMed ID: 17560680
[TBL] [Abstract][Full Text] [Related]
40. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation.
Mattos ÂZ; Mattos AA; Ribeiro RA
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):345-51. PubMed ID: 26649801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
